RxSight (RXST) Cash & Equivalents (2020 - 2026)

RxSight (RXST) has reported Cash & Equivalents for 7 consecutive years, with $208.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 8.22% year-over-year to $208.8 million; the trailing twelve-month figure through Jun 2026 stood at $208.8 million (down 8.22% YoY), and the FY2025 full-year result was $228.1 million, down 3.84% from the prior year.
• Cash & Equivalents declined to $208.8 million in Q2 2026 per RXST's latest filing, from $217.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $237.2 million in Q4 2024 and bottomed at $105.8 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $179.1 million across 5 years, with a median of $181.4 million in 2023.
• The widest YoY moves for Cash & Equivalents: up 108.43% in 2022, down 33.58% in 2022.
• Over 5 years, Cash & Equivalents stood at $105.8 million in 2022, then grew by 20.23% to $127.2 million in 2023, then jumped by 86.48% to $237.2 million in 2024, then retreated by 3.84% to $228.1 million in 2025, then declined by 8.46% to $208.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $208.8 million, $217.9 million, and $228.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.